A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313
This study is recruiting at 8 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hepatocellular Carcinoma
- Squamous Cell Non-Small Cell Lung Cancer
- Germ Cell Tumor
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Zymeworks BC Inc.
- Last updated on ClinicalTrials.gov
- October 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- UCSF Comprehensive Cancer Center · San Francisco, CA
- University of California Los Angeles - Cancer Care - Santa Monica (UCLA) · Santa Monica, CA
Kentucky · 1
- Norton Cancer Institute · Louisville, KY
Michigan · 1
- START Midwest · Grand Rapids, MI
New Jersey · 1
- Hackensack University Medical Center · Hackensack, NJ
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
Texas · 2
- MD Anderson Cancer Center · Houston, TX
- START San Antonio · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.